

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 5

**Complete if Known**

|                        |                        |
|------------------------|------------------------|
| Application Number     | 10/586,501             |
| Filing Date            | September 14, 2007     |
| First Named Inventor   | Martin HENDRIX, et al. |
| Art Unit               | 1624                   |
| Examiner Name          | Rao Deepak R.          |
| Attorney Docket Number | 01-2118                |

**U.S. PATENT DOCUMENTS**

| Examiner Initials * | Cite No. <sup>1</sup> | Document Number                            | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of<br>Cited Document | Pages, Columns, Lines, Where Relevant<br>Passages or Relevant<br>Figures Appear |
|---------------------|-----------------------|--|--------------------------------|--|---|
|                     |                       | Number - Kind Code <sup>2</sup> (if known) |                                |  |   |
|                     |                       | 2007/0161662 A1                            | 07-12-2007                     | Martin HENDRIX, et al.                             |   |
|                     |                       | 2006-0111372 A1                            | 05-25-2006                     | Martin HENDRIX, et al.                             |   |
|                     |                       | 2006/0106035 A1                            | 05-18-2006                     | Martin HENDRIX, et al.                             |   |
|                     |                       | 2006-0100222 A1                            | 05-11-2006                     | Frank-Gerhard BOSS, et al.                         |   |
|                     |                       | 2004/0266736 A1                            | 12-30-2004                     | Frank WUNDER, et al.                               |   |
|                     |                       | 2007/0105876 A1                            | 05-10-2007                     | Martin HENDRIX, et al.                             |   |
|                     |                       | 5,256,668                                  | 10-26-1993                     | Kuo-HOM, et al.                                    |   |
|                     |                       | 5,977,118                                  | 11-2-1999                      | Edward R. BACON, et al.                            |   |
|                     |                       | 5,002,949                                  | 3-26-1991                      | Steven M. PESECKIS, et al.                         |   |
|                     |                       | 3,732,225                                  | 05-08-1973                     | Hermann BREUER, et al.                             |   |
|                     |                       | 3,165,520                                  | 01-12-1965                     | Paul SCHMIDT, et al.                               |   |

**FOREIGN PATENT DOCUMENTS**

| Examiner Initials *   | Cite No. <sup>1</sup> | Foreign Patent Document  | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of Cited<br>Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>2</sup> |
|-----------------------|-----------------------|--|--------------------------------|--|--|----------------|
|                       |                       | Country Code <sup>3</sup> - Number <sup>3</sup> - Kind<br>Code <sup>2</sup> (if known) |                                |  |  |                |
|                       |                       | CA 2 484 997 A1  | 04-22-2003                     | Bayer Cropscience AG                               |  |                |
|                       |                       | CA 2 417 631 A1  | 01-29-2003                     | Bayer Aktiengesellschaft                           |  |                |
|                       |                       | CA 2 438 890 A1  | 09-06-2002                     | Bayer Aktiengesellschaft                           |  |                |
|                       |                       | CA 2 496 194 A1  | 03-04-2004                     | Bayer Healthcare AG                                |  |                |
|                       |                       | CA 2 496 292 A1  | 04-01-2004                     | Bayer Healthcare AG                                |  |                |
|                       |                       | CA 2 496 308 A1  | 04-01-2004                     | Bayer Healthcare AG                                |  |                |
|                       |                       | CA 2 283 211 A1  | 09-17-1998                     | Bayer Aktiengesellschaft                           |  |                |
|                       |                       | CH 396 923   | 01-31-1966                     | CIBA Aktiengesellschaft                            |  |                |
|                       |                       | CH 396 924   | 01-31-1966                     | CIBA Aktiengesellschaft                            |  |                |
|                       |                       | CH 396 925   | 01-31-1966                     | CIBA Aktiengesellschaft                            |  |                |
|                       |                       | CH 396 926   | 01-31-1966                     | CIBA Aktiengesellschaft                            |  |                |
|                       |                       | CH 396 927   | 01-31-1966                     | CIBA Aktiengesellschaft                            |  |                |
|                       |                       | DE 1 153 023   | 08-22-1963                     | CIBA Aktiengesellschaft                            |  |                |
|                       |                       | DE 1 149 013   | 05-22-1963                     | CIBA Aktiengesellschaft                            |  |                |
|                       |                       | DE 2 408 906   | 09-19-1974                     | Chemische Fabrik von<br>Heyden GmbH                |  |                |
|                       |                       | DE 1 156 415   | 10-31-1963                     | CIBA Aktiengesellschaft                            |  |                |
|                       |                       | DE 101 56 249  | 05-28-2003                     | Bayer, AG  |  |                |
|                       |                       | DE 1 147 234   | 04-18-1963                     | CIBA Aktiengesellschaft                            |  |                |
|                       |                       | EP 0 995 751 A2  | 04-26-2000                     | Pfizer Inc.  |  |                |
| Examiner<br>Signature |                       |  |                                | Date<br>Considered                                 |  |                |

\*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

|                        |                        |
|------------------------|------------------------|
| Application Number     | 10/586,501             |
| Filing Date            | September 14, 2007     |
| First Named Inventor   | Martin HENDRIX, et al. |
| Art Unit               | 1624                   |
| Examiner Name          | Rao Deepak R.          |
| Attorney Docket Number | 01-2118                |

Sheet 2 of 5

**FOREIGN PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T <sup>2</sup> |
|--------------------|-----------------------|-------------------------|-----------------------------|---|---|----------------|
|                    |                       | GB 937,726              | 09-25-1963                  | CIBA Limited                                    |   |                |
|                    |                       | GB 973,361              | 10-28-1964                  | CIBA Limited                                    |   |                |
|                    |                       | WO 02/055082 A1         | 07-18-2002                  | Vernalis Research Limited                       |   |                |
|                    |                       | WO 02/06288 A1          | 01-24-2002                  | F. Hoffmann-La Roche AG                         |   |                |
|                    |                       | WO 2004/018474 A1       | 03-04-2004                  | Bayer Healthcare AG                             |   |                |
|                    |                       | WO 2004/026286 A3       | 04-01-2004                  | Bayer Healthcare AG                             |   |                |
|                    |                       | WO 02/068423 A1         | 09-06-2002                  | Bayer Aktiengesellschaft                        |   |                |
|                    |                       | WO 02/097113 A2         | 02-07-2002                  | Bayer Aktiengesellschaft                        |   |                |
|                    |                       | WO 03/093269 A2         | 11-13-2003                  | Bayer Cropscience AG                            |   |                |
|                    |                       | WO 03/037899 A1         | 05-08-2003                  | Pfizer Limited                                  |   |                |
|                    |                       | WO 03/041725 A2         | 05-22-2003                  | Bayer Aktiengesellschaft                        |   |                |
|                    |                       | WO 99/41253             | 08-19-1999                  | Tularik Inc.                                    |   |                |
|                    |                       | WO 98/40384             | 09-17-1998                  | Bayer Aktiengesellschaft                        |   |                |
|                    |                       | WO 98/10765             | 03-19-1998                  | The Board of Trustees                           |   |                |
|                    |                       | WO 2004/026286 A2       | 04-01-2004                  | Bayer Healthcare AG                             |   |                |
|                    |                       | WO 2004/026876 A1       | 04-01-2004                  | Bayer Healthcare AG                             |   |                |
|                    |                       | WO 2004/026286 A1       | 04-01-2004                  | Bayer Healthcare AG                             |   |                |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|--------------------|-----------------------|---|----------------|
|                    |                       | F. Josel van der STAAY, et al., "The novel selective PDE9 inhibitor BAY 73-6591 improves learning and memory in rodents", NEUROPHARMACOLOGY, 55 (2008) pp. 908-916  |                |
|                    |                       | U. EBERT, et al., "Scopolamine model of dementia: electroencephalogram findings and cognitive performance", EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, (1998) 28, pp. 944-949  |                |
|                    |                       | Jos PRICKAERTS, et al., "Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: Effect of 7-nitroindazole and zaprinast", EUROPEAN JOURNAL OF PHARMACOLOGY 337 (1997) pp. 125-136   |                |
|                    |                       | F. Zaragoza DÖRWALD, "Side Reactions in Organic Synthesis", A GUIDE TO SUCCESSFUL SYTHESIS DESIGN, 2005, 4 pages  |                |
|                    |                       | Kenneth F. PODRAZA, "Reductive Cyclization of Ketoesters Utilizing Sodium Cyanoborohydride: Synthesis of $\gamma$ - and $\delta$ -Lactones" J. HETEROCYCLIC CHEM., 24, 193 (1987)   |                |
| Examiner Signature |                       | Date Considered   |                |

\*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

|                        |                        |
|------------------------|------------------------|
| Application Number     | 10/586,501             |
| Filing Date            | September 14, 2007     |
| First Named Inventor   | Martin HENDRIX, et al. |
| Art Unit               | 1624                   |
| Examiner Name          | Rao Deepak R.          |
| Attorney Docket Number | 01-2118                |

Sheet 3 of 5

**NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials * | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|---------------------|-----------------------|---|----------------|
|                     |                       | Internet Article, "Amnesia", From Wikipedia, the free encyclopedia, 3 pages   |                |
|                     |                       | Reid IA, "Role of phosphodiesterase isoenzymes in the control of rennin secretion: effects of selective enzyme inhibitors", CURR PHARM DES, 1999, Sep; 5(9): 725-35   |                |
|                     |                       | Edwin J. WEEBER, et al., "Molecular Genetics of Human Cognition", MOLECULAR INVENTIONS, Vol. 2, Issue 6, October 2002, pps. 376-391   |                |
|                     |                       | International Search Report for International Application No. PCT/EP2004/004455 mailed September 17, 2004, 8 pages  |                |
|                     |                       | International Search Report for International Application No. PCT/EP2004/004412 mailed July 14, 2004, 6 pages   |                |
|                     |                       | International Search Report for International Application No. PCT/EP03/08979 mailed November 25, 2003, 8 pages  |                |
|                     |                       | International Search Report for International Application No. PCT/EP03/08923 mailed December 15, 2003, 6 pages  |                |
|                     |                       | International Search Report for International Application No. PCT/EP2004/008477 mailed October 27, 2004, 8 pages  |                |
|                     |                       | International Search Report for International Application No. PCT/EP2004/014872 mailed May 19, 2005, 10 pages   |                |
|                     |                       | Scott H. SODERLING, et al., "Identification and Characterization of a Novel Family of Cyclic Nucleotide Phosphodiesterases", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 273, No. 25, Issue of June 19, 1998, pgs. 15553-15558                                    |                |
|                     |                       | Scott H. SODERLING, et al., "Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions", CURRENT OPINION IN CELL BIOLOGY, 2000, 12:174-179  |                |
|                     |                       | Svetlana G. ANDREEVA, et al., "Expression of cGMP-Specific Phosphodiesterase 9A mRNA in the Rat Brain", THE JOURNAL OF NEUROSCIENCE, November 15, 2001, 21(22); pgs. 9068-9076  |                |
|                     |                       | C. C. CHENG, et al., "Potential Purine Antagonist VII. Synthesis of 6-Alkylpyrazolo-[3,4-d]pyrimidines <sup>10a</sup> ", POTENTIAL PURINE ANTAGONISTS, VII, Vol. 23, February 1958, pgs. 191-200  |                |
|                     |                       | Lindsay FAWCETT, et al., "Molecular cloning and characterization of a distance human phosphodiesterase gene family: PDE11A", PNAS, Vol. 97, No. 7, March 28, 2000, pgs. 3702-3707   |                |
|                     |                       | Douglas A. FISHER, et al., "Isolation and Characterization of PDE9A, a Novel Human cGMP-specific Phosphodiesterase", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 273, No. 25, Issue of June 19, 1998, pgs. 15559-15564  |                |
| Examiner Signature  |                       | Date Considered   |                |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete if Known**

|                        |                        |
|------------------------|------------------------|
| Application Number     | 10/586,501             |
| Filing Date            | September 14, 2007     |
| First Named Inventor   | Martin HENDRIX, et al. |
| Art Unit               | 1624                   |
| Examiner Name          | Rao Deepak R.          |
| Attorney Docket Number | 01-2118                |

Sheet 4 of 5

**NON PATENT LITERATURE DOCUMENTS**

- Douglas A. FISHER, et al., "Isolation and Characterization of PDE9A, A Novel Human cAMP-Specific Phosphodiesterase", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 246, April 15, 1998, pgs. 570-577
- Sharon H. FRANCAIS, et al., "Characterization of a Novel cGMP Binding Protein from Rat Lung", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 255, No. 2, Issue of January 25, 1980, pgs. 620-626
- Kotomi FUJISHIGE, et al., "Cloning and Characterization of a Novel Human Phosphodiesterase That Hydrolyzes Both cAMP and cGMP (PDE10A)", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 274, No. 26, Issue of June 25, 1999, pgs. 18438-18445
- Helke GIELEN, et al., "A novel approach to amides from esters", TETRAHEDRON LETTERS, 43, 2002, pgs. 419-421
- Rudolf GOMPPER, et al., "Substituted dithiocarboxylic acids and ketene thioacetals", CARBOXYLIC ACID DERIVATIVES, Vol. 95, 1992, pgs. 2861-2870
- Peter G. GILLESPIE, et al., "Characterization of a Bovine Cone Photoreceptor Phosphodiesterase Purified by Cyclic GMP-Sepharose Chromatography", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 263, No. 17, Issue of June 15, 1988, pgs. 8133-8141
- Michel GUIPPONI, et al., "Identification and characterization of a novel cyclic nucleotide phosphodiesterase gene (PDE9A) that maps to 21q22.3: alternative splicing of mRNA transcripts, genomic structure and sequence", HUM GENET (1998) 103:366-392
- J.M. HETMAN, et al., "Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase", PNAS, Vol. 97, No. 1, January 4, 2000, pgs. 472-476
- Kate LOUGHNEY, et al., "Isolation and Characterization of cDNAs Corresponding to Two Human Calcium, Calmodulin-regulated, 3',5'-Cyclic Nucleotide Phosphodiesterases", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 271, No. 2, Issue of January 12, 1996, pgs. 796-806
- James E. HUETTNER, et al., "Primary Culture of Identified Neurons from the Visual Cortex of Postnatal Rats", THE JOURNAL OF NEUROSCIENCE, Vol. 6, No. 10, pgs. 3044-3060
- Kate LOUGHNEY, et al., "Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase", GENE, 216 (1998), pgs. 139-147
- Clair LUGNIER, "Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents", PHARMACOLOGY & THERAPEUTICS, 109 (2006), pgs. 366-398
- Timothy J. MARTINS, et al., "Purification and Characterization of a Cyclic GMP-stimulated Cyclic Nucleotide Phosphodiesterase from Bovine Tissues", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 257, No. 4, Issue of February 25, 1981, pgs. 1973-1979
- Akira MIYASHITA, et al., "Studies on Pyrazolo[3,4-d]Pyrimidine Derivatives", HETEROCYCLE, Vol. 31, No. 7, 1999, pgs. 1309-1314
- Takashi MIKI, et al., "Characterization of the cDNA and Gene Encoding Human PDE3B, the cGIP1 Isoform of the Human Cyclic GMP-Inhibited Cyclic Nucleotide Phosphodiesterase Family", GENOMICS, 36, 1996, pgs. 476-485
- Seiko MURASHIMA, et al., "Characterization of Particulate Cyclic Nucleotide Phosphodiesterases from Bovine Brain: Purification of a Distinct cGMP-Stimulated Isozyme", BIOCHEMISTRY, Vol. 29, 1990, pgs. 5285-5292
- Rena OBERNOTLE, et al., "The cDNA of a human lymphocyte cyclic-AMP phosphodiesterase (PDE IV) reveals a multigene family", GENE, Vol. 29, 1993, pgs. 239-247

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional): \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete If Known**

|                        |                        |
|------------------------|------------------------|
| Application Number     | 10/586,501             |
| Filing Date            | September 14, 2007     |
| First Named Inventor   | Martin HENDRIX, et al. |
| Art Unit               | 1624                   |
| Examiner Name          | Rao Deepak R.          |
| Attorney Docket Number | 01-2118                |

Sheet 5 of 5

Attorney Docket Number 01-2118

**NON PATENT LITERATURE DOCUMENTS**

|  |   |  |
|--|---|--|
|  | K. Hemender REDDY, et al., "Versatile synthesis of 6-alkyl/aryl-1H-pyrazolo[3,4-d]pyrimidin-4[5H]-ones", INDIAN JOURNAL OF CHEMISTRY, Vol. 31B, March 1992, pgs. 163-166  |  |
|  | Magnus ROENN, et al., "Palladium (II)-Catalyzed Cyclization Using Molecular Oxygen as Reoxidant", TETRAHEDRON LETTERS, Vol. 36, No. 42, 1995, pgs. 7749-7752  |  |
|  | Guy J. ROSMAN, et al., "Isolation and Characterization of human cDNAs encoding a cGMP-stimulated 3',5'-cyclic nucleotide phosphodiesterase", GENE, Vol. 191, 1997, pgs. 89-95   |  |
|  | P. SCHMIDT, et al., "A new synthesis of pyrazolo [3,4-d] pyrimidines having coronary dilation properties", HELVETICA CHIMICA ACTA, Volume XLV, fascicule V (1962) No. 189, pgs. 1620-1627                             |  |
|  | Arne SCHOUSBOE, et al., "Role of CA <sup>2+</sup> and Other Second Messengers in Excitatory Amino Acid Receptor Mediated Neurodegeneration: Clinical Perspectives", CLINICAL NEUROSCIENCE, Vol. 4, 1997, pgs. 194-198 |  |
|  | Joachim ULIRCH, "Crystallization", KIRK-OTTMER ENCYCLOPEDIA OF CHEMICAL TECHNOLOGY, August 16, 2002, 7 pages  |  |
|  | Anthony R. WEST, "Solid Solutions", Department of Chemistry University of Aberdeen, March 3, 1988, 3 pages  |  |
|  | Sudha R. VIPPAGUNTA, et al., "Crystalline Solids", ADVANCED DRUG DELIVERY REVIEWS, Vol. 48, 2001, pgs. 3-26   |  |
|  | Ji-Ye WEI, et al., "Molecular and Pharmacological Analysis of Cyclic Nucleotide-Gated Channel Function in the Central Nervous System", PROGRESS IN NEUROBIOLOGY, Vol. 56, 1998, pgs. 37-64                            |  |
|  | Internet Article, "Dementia", Information from the Mental Health Foundation, March 19, 2008, 3 pages  |  |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.